Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (NASDAQ: ATRA) and Jounce Therapeutics Inc (NASDAQ: JNCE)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atara Biotherapeutics (NASDAQ: ATRA) and Jounce Therapeutics Inc (NASDAQ: JNCE) with bullish sentiments.

Atara Biotherapeutics (NASDAQ: ATRA)

Canaccord Genuity analyst John Newman reiterated a Buy rating on Atara Biotherapeutics (NASDAQ: ATRA) yesterday and set a price target of $47. The company’s shares opened today at $19.05.

According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -7.8% and a 35.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $23.

Jounce Therapeutics Inc (NASDAQ: JNCE)

Cowen & Co. analyst Boris Peaker reiterated a Buy rating on Jounce Therapeutics Inc (NASDAQ: JNCE) yesterday. The company’s shares opened today at $24.84.

Peaker wrote:

“Jounce announced initiation of the Phase 2 portion of the ICONIC study of JTX-2011.”

According to TipRanks.com, Peaker is a 3-star analyst with an average return of 3.5% and a 41.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, and Merrimack Pharmaceuticals.

Jounce Therapeutics Inc has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.